

## FREEDOM OF INFORMATION REQUEST

### 1. What steps has your CCG/Trust taken to ensure compliance with the mandatory NICE tag 664 for Saxenda. If none, what plans are in place to address this?

NICE has recommended Liraglutide (Saxenda®) as an option for managing overweight and obesity alongside a reduced-calorie diet and increased physical activity in adults, only if:

- they have a body mass index (BMI) of at least 35 kg/m<sup>2</sup> (or at least 32.5 kg/m<sup>2</sup> for members of minority ethnic groups known to be at equivalent risk of the consequences of obesity at a lower BMI than the white population) and
- they have non-diabetic hyperglycaemia (defined as a haemoglobin A1c level of 42 mmol/mol to 47 mmol/mol [6.0% to 6.4%] or a fasting plasma glucose level of 5.5 mmol/litre to 6.9 mmol/litre) and
- they have a high risk of cardiovascular disease based on risk factors such as hypertension and dyslipidaemia and
- it is prescribed in secondary care by a specialist multidisciplinary tier 3 weight management service and
- the company provides it according to the commercial arrangement.

NICE TA664 requires the treatment to be prescribed in secondary care by a specialist multidisciplinary Tier 3 weight management service which is currently not available in Northern Ireland. The Department of Health has issued correspondence to HSCB confirming that the issuing of the Service Notification in respect of TA664 be deferred until the work being taken forward by the Department to establish a Tier 3 service as part of a wider regional obesity management service has been able to progress sufficiently to support the provision of this treatment regime. This is unlikely to be before 2022/23.

### 2. Have patients that are eligible to utilise the NICE approved product Saxenda been able to access this product? If so please provide the volume, or if not, please provide any current plans to address this.

As above, the Department of Health has issued correspondence to HSCB confirming that the issuing of the Service Notification in respect of TA664 be deferred until the work being taken forward by the Department to establish a Tier 3 service as part of a wider regional obesity management service has been able to progress sufficiently to support the provision of this treatment regime. This is unlikely to be before 2022/23.